Clinical Report

Reality of obesity paradox: Results of percutaneous coronary intervention in Middle Eastern patients

Mohamad Jarrah¹, Ayman J. Hammoudeh², Yousef Khader³, Ramzi Tabbalat⁴, Eyas Al-Mousa², Osama Okkeh⁵, Imad A. Alhaddad⁶, Loai Issa Tawalbeh⁷ and Issa M. Hweidi⁸

Abstract

Objective: The aim of this study was to assess the baseline clinical characteristics, coronary angiographic features, and adverse cardiovascular events during hospitalization and at 1 year of follow-up in obese patients compared with overweight and normal/underweight patients.

Methods: A prospective, multicenter study of consecutive patients undergoing percutaneous coronary intervention was performed.

Results: Of 2425 enrolled patients, 699 (28.8%) were obese, 1178 (48.6%) were overweight, and 548 (22.6%) were normal/underweight. Obese patients were more likely to be female and to have a higher prevalence of diabetes, hypertension, hypercholesterolemia, or previous percutaneous coronary intervention. Acute coronary syndrome was the indication for percutaneous coronary intervention in 77.0% of obese, 76.4% of overweight, and 77.4% of normal/underweight patients. No significant differences in the prevalence of multi-vessel coronary artery disease or multi-vessel percutaneous coronary intervention were found among the three groups. Additionally, no significant differences were found in stent thrombosis, readmission bleeding
rates, or cardiac mortality among the three groups during hospitalization, at 1 month, and at 1 year.

**Conclusion:** The major adverse cardiovascular event rate was the same among the three groups throughout the study period. Accordingly, body mass index is considered a weak risk factor for cardiovascular comorbidities in Arab Jordanian patients.

**Keywords**
Cardiovascular disease, obesity, obesity paradox, Middle Eastern patients, percutaneous coronary intervention, major adverse cardiovascular events

Date received: 20 July 2017; accepted: 11 January 2018

**Introduction**

Cardiovascular disease is the leading cause of death in the Middle East. Obesity, an established cardiovascular risk factor, is highly prevalent in the general population in the region and among patients admitted with acute coronary syndrome (ACS). Obese patients admitted with ACS or those who undergo percutaneous coronary intervention (PCI) may have a more favorable outcome than underweight or normal patients. The potential presence of the “obesity paradox” and its impact on 1-year outcomes in Middle Eastern patients who undergo PCI for ACS or stable coronary disease has not been addressed by large ACS or PCI registries. The two regional studies that evaluated outcomes in obese patients reached conflicting conclusions about the in-hospital event rates, and neither evaluated the outcome at 1 year. The first showed no difference in the inhospital outcome across body mass index (BMI) groups among patients admitted with ACS. The other demonstrated better in-hospital outcomes in overweight and obese patients who underwent elective PCI. Our study is unique in that it is the first to evaluate the short- and long-term outcomes of patients who underwent PCI in the Middle East, a region in the world that is not well represented among cardiovascular interventional studies. Therefore, this study was performed to assess the baseline clinical characteristics and coronary angiographic features and the adverse cardiovascular events during hospitalization, at 1 month, and at 1 year after discharge in obese patients compared with those in overweight and normal/underweight patients using data from the recently completed first Jordanian PCI Registry (JoPCR1).

**Methods**

**Design and setting**

This study was a prospective, multicenter, observational study involving consecutive patients who underwent PCI for ACS or stable coronary disease in 12 tertiary care hospitals in Jordan from January 2013 to February 2014. The methods were extensively explained in previous reports.

**Data collection and measurement**

Briefly, a case report form was used to record data at hospital admission, at discharge, and at 1 and 12 months of follow-up. Data were
collected during follow-up clinic visits or phone calls to the patient, household relative, or primary care physician. The patients’ clinical characteristics were collected through a review of their medical records. The baseline data included clinical, laboratory, electrocardiographic, echocardiographic, and coronary angiographic features. BMI was calculated according to the standard formula (body weight [kg]/height [m]^2). Weight and height were measured as early as possible after hospital admission and when the clinical situation of each patient was stable enough to allow these measurements. Details of the PCI procedures and in-hospital complications were documented. All PCI procedures were performed according to current standard guidelines. The arterial access site, antiplatelet therapy, and type of stent used were at the operator’s discretion.

ACS was classified as acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation ACS (NSTEMI), which included non-STEMI and unstable angina. Stable coronary disease included chronic stable angina and silent ischemia.

Clinical profiles, coronary angiographic features, and periprocedural complications were compared among three groups of patients according to BMI: obese (BMI of \( \geq 30 \) kg/m\(^2\)), overweight (BMI of 25–29.9 kg/m\(^2\)), and normal/underweight (BMI of <25 kg/m\(^2\)). We also compared the incidence of adverse cardiovascular events including cardiac mortality, stent thrombosis, major bleeding events, and readmission for patients with heart failure, with ACS, and who underwent coronary revascularization among the three groups up to 1 year of follow-up. Cardiac mortality was defined as any death not attributed to a clear non-cardiac cause. Stent thrombosis, definite or probable, was defined according to the Academic Research Consortium definition. Major bleeding events were defined according to the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) study definition and included intracranial hemorrhage, retroperitoneal bleeding, a \( \geq 12\% \) decrease in hematocrit from baseline, any red blood cell transfusion when the baseline hematocrit was \( \geq 28\% \), or any transfusion when the baseline hematocrit was \( <28\% \) with witnessed bleeding. The study was approved by the Institutional Review Board of each participating hospital, and patients provided written informed consent.

**Statistical analysis**

IBM SPSS Statistics 20 (IBM Corp., Armonk, NY, USA) was used for data entry and analysis. Data are described using means and percentages. The chi-square test was used to assess differences in proportions among the three groups, and one-way analysis of variance was used to assess differences in means among the three groups. A binary logistic regression was used to assess differences in the rates of stent thrombosis, major bleeding, and cardiac mortality during the index hospitalization, at 1 month, and at 1 year among the three groups after adjusting for other variables. A P-value of <0.05 was considered statistically significant.

**Results**

**Sample characteristics**

The registry enrolled 2425 consecutive patients who underwent PCI, including 1857 (76.6%) with ACS and 568 (23.4%) with stable coronary disease. The BMI (mean ± standard deviation) was 28.5 ± 4.5 kg/m\(^2\). The study population comprised 699 (28.8%) obese, 1178 (48.6%) overweight, and 548 (22.6%) normal/underweight patients.

The baseline demographic characteristics and risk factor profiles in the three groups
of patients are presented in Table 1. Obese patients tended to be younger (although not significantly so) and were more likely to be female (P < 0.001); to have hypertension (P < 0.001), diabetes mellitus (P = 0.02), hypercholesterolemia (P < 0.001), a family history of premature cardiovascular disease (P = 0.004), and a history of PCI (P = 0.002); and to use renin angiotensin-aldosterone system blockers compared with the other two groups. Obese patients were less likely to be smokers or have renal impairment. There were no significant differences in age, the rate of ST-segment deviation on electrocardiography, elevated blood levels of cardiac biomarkers, heart failure or a low left ventricular ejection fraction, prior myocardial infarction, chronic renal disease, and the use of drugs other than renin angiotensin-aldosterone system blockers among the three groups.

As indicated in Table 2, similar proportions of patients in the three groups underwent PCI for STEMI, NSTEMI, or stable coronary disease. The severity of coronary artery disease and the rate of PCI for multi-vessel disease were also not different among the three groups. The rate of periprocedural complications in obese patients during the index hospitalization was not different from that in the two other groups, and the length of hospital stay was also similar among the three groups. Obese patients were less likely to have a high Global

### Table 1. Baseline features in three groups of patients stratified by BMI.

| Clinical feature | BMI ≥30 kg/m² | BMI 25.0–29.9 kg/m² | BMI <25 kg/m² | P |
|------------------|--------------|---------------------|---------------|---|
| Age (years)      | 57.8 ± 10.7  | 58.3 ± 10.7         | 59.3 ± 11.4   | 0.06 |
| Female           | 222 (31.8)   | 190 (16.1)          | 88 (16.1)     | <0.001 |
| Hypertension     | 484 (69.2)   | 715 (60.7)          | 312 (56.9)    | <0.001 |
| Hypercholesterolemia | 382 (54.6) | 584 (49.5)          | 218 (39.8)    | <0.001 |
| Current cigarette smoking | 270 (38.6)  | 517 (43.9)          | 268 (48.9)    | 0.003 |
| Family history of premature CVD | 304 (43.5) | 465 (39.5)          | 188 (34.3)    | 0.004 |
| Chronic renal disease | 22 (3.1)    | 24 (2.0)            | 23 (4.2)      | 0.14 |
| eGFR of <60 mL/min | 47 (6.7)    | 141 (12.0)          | 130 (23.7)    | 0.001 |
| Diabetes mellitus | 398 (56.9)  | 627 (53.2)          | 275 (50.2)    | 0.02 |
| Prior MI         | 84 (12.0)    | 114 (9.7)           | 65 (11.9)     | 0.60 |
| Prior PCI        | 197 (28.2)   | 284 (24.1)          | 108 (19.7)    | 0.002 |
| Medications prior to admission |  |  |  | |
| Aspirin          | 455 (65.1)   | 764 (65.0)          | 349 (63.7)    | 0.85 |
| Clopidogrel      | 144 (20.6)   | 248 (21.1)          | 140 (25.5)    | 0.07 |
| Beta blockers    | 334 (47.8)   | 558 (47.4)          | 258 (47.1)    | 0.97 |
| RAASB            | 309 (44.2)   | 477 (40.5)          | 201 (36.7)    | 0.03 |
| Statins          | 372 (53.2)   | 614 (52.1)          | 280 (51.1)    | 0.77 |
| ST-segment deviation | 340 (48.6) | 565 (48.0)          | 276 (50.4)    | 0.32 |
| Elevated levels of cardiac enzymes | 262 (37.5) | 482 (40.9)          | 226 (41.2)    | 0.28 |
| LVEF of <45%     | 78 (11.2)    | 153 (13.0)          | 71 (13.0)     | 0.47 |
| Heart failure    | 70 (10.0)    | 140 (11.9)          | 59 (10.8)     | 0.48 |

Data are presented as mean ± standard deviation or n (%).

BMI: body mass index; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; MI: myocardial infarction; PCI: percutaneous coronary intervention; RAASB: renin angiotensin-aldosterone system blockers.
Table 2. Indications for PCI, details of coronary angiography and PCI, CAD characteristics, and in-hospital complications in three groups of patients stratified by BMI.

| Clinical feature                  | BMI ≥30 kg/m² | BMI 25.0–29.9 kg/m² | BMI <25 kg/m² | P       |
|----------------------------------|---------------|---------------------|---------------|---------|
| **PCI indication**               | n = 699       | n = 1178            | n = 548       |         |
| STEMI                            | 195 (27.9)    | 360 (30.6)          | 170 (31.0)    | 0.62    |
| NSTEACS                          | 343 (49.1)    | 540 (45.8)          | 249 (45.4)    |         |
| Stable coronary syndrome         | 161 (23.0)    | 278 (23.6)          | 129 (23.5)    |         |
| **In-hospital medications**      |               |                     |               |         |
| Aspirin                          | 690 (98.7)    | 1164 (98.8)         | 542 (98.9)    | 0.45    |
| Second oral antiplatelet         | 684 (97.9)    | 1157 (98.2)         | 545 (99.5)    | 0.06    |
| Thrombolysis                     | 20 (2.9)      | 39 (3.3)            | 22 (4.0)      | 0.52    |
| GPI                              | 92 (13.2)     | 162 (13.8)          | 73 (13.3)     | 0.92    |
| Beta blockers                    | 550 (78.7)    | 937 (79.5)          | 436 (79.6)    | 0.78    |
| RAASB                            | 457 (65.4)    | 723 (61.4)          | 322 (58.8)    | 0.06    |
| Statins                          | 680 (97.3)    | 1148 (97.5)         | 529 (96.5)    | 0.49    |
| **GRACE risk score**             |               |                     |               |         |
| On admission                     | 111.4 ± 34.1  | 115.4 ± 35.7        | 119.8 ± 36.8  | 0.001   |
| Pre-discharge                    | 71.9 ± 22.1   | 73.3 ± 22.6         | 76.0 ± 24.5   | 0.007   |
| **CRUSADE bleeding risk score**  |               |                     |               |         |
| One vessel                       | 20.5 ± 13.8   | 21.9 ± 13.4         | 25.7 ± 13.9   | <0.001  |
| Multi-vessel                     | 419 (59.9)    | 690 (58.6)          | 308 (56.4)    |         |
| PCI                              | 280 (40.1)    | 489 (41.5)          | 240 (43.8)    |         |
| One vessel                       | 510 (73.0)    | 850 (72.2)          | 380 (69.3)    | 0.62    |
| Multi-vessel                     | 180 (25.7)    | 316 (26.8)          | 162 (29.6)    |         |
| LMCA                             | 9 (1.3)       | 12 (1.0)            | 6 (1.1)       |         |
| **In-hospital complications**    |               |                     |               |         |
| Ventricular tachyarrhythmia      | 1 (0.1)       | 11 (0.9)            | 3 (0.5)       | 0.08    |
| Heart failure                    | 51 (7.3)      | 98 (8.3)            | 45 (8.2)      | 0.72    |
| Cardiogenic shock                | 4 (0.6)       | 10 (0.8)            | 0 (0.0)       | 0.10    |
| Emergency CABG                   | 1 (0.1)       | 1 (0.1)             | 1 (0.2)       | 0.85    |
| Vascular access hematoma         | 21 (3.0)      | 28 (2.4)            | 17 (3.1)      | 0.62    |
| **Length of stay**               |               |                     |               | 0.96    |
| ≤1 day                           | 216 (30.9)    | 361 (30.6)          | 170 (31.0)    |         |
| 2–3 days                         | 420 (60.1)    | 709 (60.2)          | 334 (60.9)    |         |
| >3 days                          | 63 (9.0)      | 108 (9.2)           | 44 (8.1)      |         |

Data are presented as mean ± standard deviation or n (%).

CAD: coronary artery disease; BMI: body mass index; CABG: coronary artery bypass graft; CRUSADE: Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines; CVD: cardiovascular disease; GPI: glycoprotein IIb/IIIa inhibitors; GRACE: Global Registry of Acute Coronary Events; LMCA: left main coronary artery; NSTEACS: non-ST-segment elevation acute coronary syndrome; PCI: percutaneous coronary intervention; RAASB: renin angiotensin-aldosterone blockers; STEMI: ST-segment elevation myocardial infarction.

Registry of Acute Coronary Events risk score both on admission and before discharge. Moreover, the CRUSADE bleeding risk score was significantly different among the three groups (P < 0.001).

Different types of stents were used in this contemporary PCI registry, including second-generation drug-eluting stents, bare metal stents, and bioabsorbable scaffolds. However, the types of stents used were not
different among the three groups of patients. At 1 year, aspirin and a second oral antiplatelet agent were used at similar rates among the three BMI groups. Furthermore, similar proportions of patients in the three groups were prescribed statins, beta blockers, renin-angiotensin blockers, glycoprotein inhibitors, and thrombolysis agents.

**Association between BMI and major cardiovascular adverse events**

The chi-square test revealed no significant association between BMI and stent thrombosis during the index hospitalization ($X^2 (2) = 1.30$), in which obese patients had an incidence rate of stent thrombosis similar to that in the other two groups. Moreover, a non-significant association was present between BMI and stent thrombosis at 1 month and 1 year after hospital discharge ($X^2 (2) = 1.40$ and 1.60, respectively). The incidence rates of cardiac mortality and major bleeding during the hospital stay at 1 month and 1 year were not significantly different among the three groups (Table 3). Moreover, the readmission rates for three major adverse events (ACS, heart failure, and coronary revascularization) were not different between the obese group and the other two groups of patients.

**Discussion**

The main findings of this contemporary Middle Eastern study of patients who underwent PCI were that obese and overweight patients accounted for 77% of all enrolled patients, obese patients had a higher prevalence of cardiovascular risk factors and comorbidities than non-obese patients, and obesity was not associated with a reduced incidence of periprocedural complications or major adverse cardiovascular events at 1 year compared with non-obese patients after adjustment for potential confounders.

| Event                      | BMI $\geq$30 kg/m$^2$ | BMI 25.0–29.9 kg/m$^2$ | BMI $<$25 kg/m$^2$ | P     |
|----------------------------|------------------------|------------------------|-------------------|-------|
| Cardiac mortality          |                        |                        |                   |       |
| In hospital                | 4 (0.57)               | 12 (1.02)              | 3 (0.55)          | 0.44  |
| At 1 month                 | 6 (0.86)               | 18 (1.54)              | 5 (0.92)          | 0.34  |
| At 1 year                  | 10 (1.44)              | 27 (2.33)              | 11 (2.05)         | 0.31  |
| Stent thrombosis           |                        |                        |                   |       |
| In hospital                | 6 (0.86)               | 3 (0.25)               | 0 (0.00)          | 0.31  |
| At 1 month                 | 13 (2.73)              | 15 (1.29)              | 3 (0.55)          | 0.11  |
| At 1 year                  | 18 (3.46)              | 22 (1.91)              | 5 (0.91)          | 0.21  |
| Major bleeding events      |                        |                        |                   |       |
| In hospital                | 8 (1.14)               | 10 (0.85)              | 5 (0.91)          | 0.81  |
| At 1 month                 | 9 (1.28)               | 11 (0.94)              | 7 (1.28)          | 0.73  |
| At 1 year                  | 10 (1.43)              | 13 (1.12)              | 7 (1.28)          | 0.84  |
| Readmission at 1 year      |                        |                        |                   |       |
| ACS                        | 43 (6.29)              | 55 (4.80)              | 26 (4.84)         | 0.34  |
| Heart failure              | 8 (1.31)               | 13 (1.13)              | 7 (1.30)          | 0.93  |
| Coronary revascularization | 24 (3.50)              | 34 (2.97)              | 15 (2.79)         | 0.74  |

Data are presented as n (%).

**ACS**: acute coronary syndrome; **BMI**: body mass index
Obesity has become a global medical and socioeconomic burden of epidemic proportions and continues to substantially contribute to the development of numerous chronic metabolic and cardiovascular diseases. The excess risk is mainly attributed to the presence of excess adipose tissue, which is capable of releasing several cytokines and bioactive mediators that play important roles in the pathogenesis of obesity-related disorders.

Obesity is also associated with insulin resistance, hyperinsulinemia, hypertension, elevated levels of low-density lipoprotein cholesterol, low levels of high-density lipoprotein cholesterol, and hypertriglyceridemia. Obesity may lead to hypertension by increasing activation of the sympathetic nervous system and angiotensin–aldosterone system. The prevalence of diabetes mellitus is higher among obese than non-obese patients, a finding that is similar between the present study and other reports. Obesity is considered a main predictor of insulin resistance that is correlated with increasing BMI and visceral fat, thus explaining the high prevalence of obesity among patients with diabetes.

In contrast, the prevalence of renal impairment was significantly higher among patients with low/normal weight than among those who were overweight and obese. This result is consistent with the findings of a study conducting by Jongha, who reported a higher prevalence of chronic kidney disease, end-stage renal disease, and worse survival among patients with a low BMI. However, another study indicated that there was no significant effect of obesity on renal function.

In regard to the adverse negative impact of obesity on the cardiovascular burden, a few studies have described paradoxically longer survival among overweight and obese adults with and without chronic diseases. The term “obesity paradox” was first described in 1999 in overweight and obese people undergoing hemodialysis and later in patients with heart failure, hypertension, ACS, diabetes mellitus, peripheral arterial disease, and stroke. Explanations of the obesity paradox are not fully clear. Adipose tissue is not only a source of harmful mediators; it is also a major endocrine organ that produces anti-inflammatory agents including soluble products that neutralize the deleterious effects of tumor necrosis factor-alpha on the myocardium. Moreover, it is capable of storing lipophilic noxious substances that are potentially toxic to the body.

An association of the obesity paradox with PCI was reported in two studies. Both concluded that patients with a BMI of 27.5 to 30 kg/m² had a reduced risk of death during a 5- and 7-year follow-up. The performance of coronary interventions in obese patients has steadily increased during the last few decades and has been shown to be associated with fewer repeated revascularizations in obese patients than non-obese patients, possibly due to a larger external elastic membrane that preserves the lumen dimensions, larger stent area, and presence of beneficial vasoactive properties that may offset the adverse effects of excess adipose tissue. In the current study, we were unable to demonstrate the existence of the obesity paradox in our PCI population. Periprocedural complications during the hospital stay, the length of hospitalization, and the incidence of major adverse cardiovascular events at 1 year were not different between the obese group and the other two groups.

Our finding of the absence of the obesity paradox in patients undergoing PCI is consistent with the findings of other studies. One possible explanation for the absence of the obesity paradox is the inherent weakness of the BMI to adequately evaluate the severity of obesity based on its inability to identify body weight
components such as fat mass, fat-free mass, and lean mass.\textsuperscript{35}

Critics of the obesity paradox have argued that this phenomenon is a product of methodological artifacts and inadequate control of confounding factors. Some have suggested that obese patients are provided a level of medical care better than that provided to others, thus mitigating the potential adverse influence of obesity.\textsuperscript{36} Furthermore, some have raised concerns about the presence of reverse causation in obese patients, which refers to illness-induced weight loss. Obese patients with chronic illnesses could be healthier in the early stages of the disease, and as the illness advances they develop unintentional weight loss, which is an extremely significant predictor of mortality.\textsuperscript{37,38} Moreover, the reviewed literature indicate that higher mortality rates among the patients in the low BMI categories could be attributed to sarcopenic obesity; i.e., low muscle mass in association with obesity. This condition exacerbates insulin resistance and dysglycemia and is associated with frailty and higher mortality rates.\textsuperscript{39,40}

Regardless of whether the obesity paradox exists, obese patients with cardiovascular disease should continue to be encouraged to lose weight.\textsuperscript{41} The safety and potential long-term benefits of purposeful weight loss in overweight and obese patients with coronary heart disease should be stressed.\textsuperscript{42}

**Limitations and recommendations**

A few limitations in our study warrant discussion. Selection bias, collection of non-randomized data, and missing or incomplete information are inherent problems associated with observational registry studies. Participation was voluntary and enrollment of consecutive patients was encouraged, but this was not verified. Patients who were admitted with ACS and died before or shortly after admission were not represented in this study. The participating hospitals are high-volume tertiary care centers, and the results may not represent PCI practice and outcomes in the whole region. Our study only included patients who underwent PCI, so it cannot be generalized to patients with ACS who were treated conservatively or underwent coronary artery bypass graft surgery. We did not evaluate outcomes in patients with a BMI of \(<20\) or \(>35\) kg/m\(^2\) separately because of the small numbers of patients in these groups (1.3% and 7.7%, respectively). We measured the BMI to define excess weight and obesity. Additionally, the BMI is a crude and flawed anthropometric biomarker that lacks the discriminating power to differentiate between lean body mass and fat mass. Although it is easy to calculate, it has problematic cut-off points, and some researchers advocate correlating events with measuring the visceral adipose tissue.\textsuperscript{39} We did not correlate survival with the BMI changes during the 1-year follow-up that could have taken place due to patients’ compliance with weight reduction advice. Weight fluctuations cannot be captured with a single BMI measurement. However, some longitudinal studies have relied on a single measure of BMI, similar to our methodology.\textsuperscript{43} Future prospective studies will be conducted using different measures for obesity such as the waist–hip ratio, fat mass, fat-free mass, and lean mass.

**Conclusions**

Obesity is associated with several medical adverse events and multiple cardiac-related risk factors, and it is recognized as an independent risk factor for cardiovascular comorbidities.\textsuperscript{40} In the current study, however, the incidence rates of major adverse cardiovascular events were the same in obese patients as in overweight and
normal/underweight patients during the hospital stay and at 1 month and at 1 year after discharge. These findings indicate that the BMI is a weak risk factor for cardiovascular comorbidities in Arab Jordanian patients.

**Acknowledgment**

The authors would like to thank Jordan University of Science and Technology for facilitating the conduction of this study.

**Declaration of conflicting interests**

The authors declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**References**

1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; 386: 743–800.

2. Poirier P, Giles TD, Bray GA, et al. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation* 2006; 113: 898–918.

3. Mallat S, Geagea A, Jurjus R, et al. Obesity in Lebanon: A national problem. *World J Cardiovasc Dis* 2016; 6: 166–174.

4. Saleh A, Hammoudeh AJ, Hamam I, et al. Prevalence and impact on prognosis of glucometabolic states in acute coronary syndrome in a Middle Eastern country: The GLucometabolic abnOrmalities in patients with acute coronaryY syndrome in Jordan (GLORY) study. *Inter J Diab Develop Countries* 2012; 32: 37–43.

5. Wang L, Liu W, He X, et al. Association of overweight and obesity with patient mortality after acute myocardial infarction: a meta-analysis of prospective studies. *Int J Obes* 2016; 40: 220–228.

6. Al Suwaidi J, Al Habib K, Asaad N, et al. Immediate and one-year outcome of patients presenting with acute coronary syndrome complicated by stroke: Findings from the 2ndGulf Registry of Acute Coronary Events (Gulf RACE-2). *BMC Cardiovascular Disorders* 2012; 12: 64. doi: 10.1186/1471-2261-12-64.

7. Mobeirek AF, Al-Habib K, Al-Faleh H, et al. Absence of obesity paradox in Saudi patients admitted with acute coronary syndromes: insights from SPACE registry. *Ann Saudi Med* 2014: 38–45.

8. Nuckchady TH, Sorour K, Gharrib S, et al. The outcome of body mass index in patients undergoing percutaneous coronary angiography. *J Saudi Heart Assoc* 2013; 25: 166–167.

9. Saleh A, Hammoudeh A, Tabbalat R, et al. Incidence and prognosis of stent thrombosis following percutaneous coronary intervention in Middle Eastern patients: The first Jordanian Percutaneous Coronary Intervention Registry (JoPCR1). *Ann Saudi Med* 2016; 36: 17–22.

10. Hammoudeh A, Tabalat R, Alhadad A, et al. Short- and long-term outcomes in Middle Eastern diabetic patients after percutaneous coronary intervention: results from The First Jordanian PCI Registry (JoPCR1). *Diabetology International* 2017; 8: 30–38.

11. Cutlip DE, Windecker S, Mehran R, et al. The academic research consortium. Clinical end points in coronary stent trials. A case for standardized definitions. *Circulation* 2007; 115: 2344–2351.

12. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of unstable angina patients Suppress Adverse outcomes with early implementation of the ACC/AHA guidelines) bleeding score. *Circulation* 2009; 119: 1873–1882.
13. Doehner W, Clark A and Stefan DA. The obesity paradox: weighing the benefit. *Eur Hear J* 2010; 31: 146–148.

14. Herrmann J, Gersh BJ, Goldfinger JZ, et al. Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial). *Am J Cardiol* 2014; 114: 9–16.

15. Calori G, Lattuada G, Piemonti L, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. *Diabetes Care* 2011; 34: 210–215.

16. Zhao W, Katzmarzyk PT, Horswell R, et al. Body mass index and the risk of all-cause mortality among patients with type 2 diabetes mellitus. *Circulation* 2014; 130: 2143–2151.

17. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes Care* 1994; 17: 961–969.

18. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. *Ann Intern Med* 1995; 122: 481–486.

19. Jongha, P. Kidney disease and obesity paradox. *Kidney Res Clin Pract* 2017; 36: 1–2.

20. Valocikova I, Valocik G, Kristofova B, et al. Obesity paradox and chronic kidney disease. *Bratisl Lek Listy* 2011; 112: 402–6.

21. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA* 2013; 309: 71–82.

22. Schmidt DS and Salahudeen AK. Cardiovascular and survival paradoxes in dialysis patients: obesity-survival paradox—still a controversy? *Seminars in Dialysis* 2007; 20: 486–492.

23. Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. *Am J Cardiol* 2015; 115: 1428–1434.

24. Niedziela J, Hudzik B, Niedziela N, et al. The obesity paradox in acute coronary syndrome: a meta-analysis. *Eur J Epidemiol* 2014; 29: 801–812.

25. Florez H and Castillo-Florez S. Beyond the obesity paradox in diabetes: fitness, fatness, and mortality. *JAMA* 2012; 308: 619–620.

26. Galal W, van Gestel YR, Hoeks SE, et al. The obesity paradox in patients with peripheral arterial disease. *Chest* 2008; 134: 925–930.

27. Vemmos K, Ntaios G, Spengos K, et al. Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. *Stroke* 2011; 42: 30–36.

28. Hong NS, Kim KS, Lee IK, et al. The association between obesity and mortality in the elderly differs by serum concentrations of persistent organic pollutants: a possible explanation for the obesity paradox. *Int J Obesity* 2011; 36: 1170–1175.

29. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. *J Am Coll Cardiol* 2001; 38: 789–795.

30. Young JQ, Damen NL, van Domburg RT, et al. Obesity, health status, and 7-year mortality in percutaneous coronary intervention: In search of an explanation for the obesity paradox. *Int J Cardiol* 2013; 167: 1154–1158.

31. Paratz ED, Wilkinson LE and MacIsaac AI. Outcomes of obese and morbidly obese patients undergoing percutaneous coronary intervention. *Heart, Lung and Circulation* 2017.

32. Kang SJ, Mintz GS, Witzenbichler B, et al. Effect of obesity on coronary atherosclerosis and outcomes of percutaneous coronary intervention: grayscale and virtual histology intravascular ultrasound substudy of assessment of dual antiplatelet therapy with drug-eluting stents. *Circ Cardiovasc Interv* 2014; 8. pii: e001392. doi: 10.1161/CIRCINTERVENTIONS.114.001392. Print 2015 Jan.

33. Buschur ME, Smith D, Share D, et al. The Burgeoning epidemic of morbid obesity in patients undergoing percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. *J Am Coll Cardiol* 2013; 62: 685–691.
34. Tobias D, Pan A and Hu FB. BMI and mortality among adults with incident type 2 diabetes. *N Engl J Med* 2014; 370: 1363–1364.

35. Vlaras E, Giakoumidakis K, Fotos NV, et al. The presence of obesity paradox in Greek patients with chronic heart failure. *Pragmat Obs Res* 2017; 8: 183-187.

36. Steinberg BA, Cannon CP, Hernandez AF, et al. Medical therapies and invasive treatments for coronary artery disease by body mass: the “obesity paradox” in the Get with the Guidelines database. *Am J Cardiol* 2007; 100: 1331–1335.

37. Tobias DK and Hu FB. Does being overweight really reduce mortality? *Obesity (Silver Spring)* 2013; 21: 1746–1749.

38. Lenzen MJ, Boersma E, Bertrand ME, et al. European Society of Cardiology. Management and outcome of patients with established coronary artery disease: Euro Heart Survey on coronary revascularization. *Eur Heart J* 2005; 26: 1169–1179.

39. Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of Obesity and Cardiovascular Risk in Ethnically and Racially Diverse Populations. A Scientific Statement from the American Heart Association. *Circulation* 2015; 132: 457–472.

40. Morley JE. Diabetes, sarcopenia, and frailty. *Clin Geriatr Med* 2008; 24: 455–469.

41. Lavie CJ, Milani RV, Artham SM, et al. The obesity paradox, weight loss, and coronary disease. *Am J Med* 2009; 122: 1106–1114.

42. Chen Y, Copeland WK, Vedanthan R, et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. 2013; *BMJ*; 347: f5446.

43. Carnethon MR. Diabetes mellitus in the absence of obesity. A risky condition. *Circulation* 2014; 130: 2131–2132.